<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00843271</url>
  </required_header>
  <id_info>
    <org_study_id>AAAA7791</org_study_id>
    <secondary_id>R01HL077612</secondary_id>
    <nct_id>NCT00843271</nct_id>
    <nct_alias>NCT00094224</nct_alias>
  </id_info>
  <brief_title>Endothelial Dysfunction, Biomarkers, and Lung Function -Ancillary to MESA</brief_title>
  <acronym>MESA-LUNG</acronym>
  <official_title>Endothelial Dysfunction, Biomarkers, and Lung Function (MESA LUNG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of MESA-Lung is to assess the role of endothelial dysfunction and genetic
      susceptibility in subclinical COPD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic obstructive pulmonary disease (COPD) is currently the fourth leading cause of death
      in the United States, and morbidity and mortality from COPD continue to rise. Despite the
      magnitude of the problem, therapeutic options are limited - particularly in comparison to
      cardiovascular disease. Smoking cessation is essential to the treatment and prevention of
      COPD. However, although smoking is the principal cause of COPD, only a minority of smokers
      develops symptomatic COPD and many former smokers develop COPD years to decades after they
      have stopped smoking. The only other medical intervention proven to reduce mortality from
      COPD is supplemental oxygen therapy. There is therefore an urgent need for newer
      understandings of the pathophysiology of COPD that might lead to the development of better
      therapies for COPD.

      MESA-Lung is ancillary of the ongoing Multi-Ethnic Study of Atherosclerosis (MESA). MESA-lung
      will utilize the various existing measures of endothelial function that have been already
      been collected in MESA (flow-mediated dilatation [FMD] and related biomarkers and gene
      polymorphisms) to test the hypotheses that the endothelial dysfunction occurs in the clinical
      COPD.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2004</start_date>
  <completion_date type="Anticipated">November 2012</completion_date>
  <primary_completion_date type="Anticipated">November 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Lung Function</measure>
    <time_frame>2004-2011</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lung Density</measure>
    <time_frame>2000-2011</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">4359</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <condition>Emphysema</condition>
  <condition>Endothelial Dysfunction</condition>
  <arm_group>
    <arm_group_label>MESA Lung</arm_group_label>
    <description>MESA-Lung is an ancillary study of the Multi-Ethnic Study of Atherosclerosis (MESA). MESA, established in 1999, is well characterized, multi-ethnic (white, Black, Hispanic and Chinese), and multi-center (Columbia, Johns Hopkins, Northwestern, UCLA, Minnesota,and Wake Forest) prospective cohort study. MESA-Lung included a 60% random sample of the MESA cohort at the six Field Centers in Exam 3 and Exam 4, stratified on race/ethnicity.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        MESA cohort
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A random sample of MESA participants active at Exam 3 and/or 4.

        Exclusion Criteria:

          -  MESA participants without MESA Exam 3 or 4 measurements.

          -  MESA participants without FMD measurements in Exam 1.

          -  MESA participants who have not consented to genetic testing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>R. Graham Barr, M.D., Dr.PH.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <link>
    <url>http://www.mesa-nhlbi.org</url>
    <description>Multi Ethnic Study of Atherosclerosis - MESA</description>
  </link>
  <results_reference>
    <citation>He K, Liu K, Daviglus ML, Mayer-Davis E, Jenny NS, Jiang R, Ouyang P, Steffen LM, Siscovick D, Wu C, Barr RG, Tsai M, Burke GL. Intakes of long-chain n-3 polyunsaturated fatty acids and fish in relation to measurements of subclinical atherosclerosis. Am J Clin Nutr. 2008 Oct;88(4):1111-8.</citation>
    <PMID>18842801</PMID>
  </results_reference>
  <results_reference>
    <citation>Jiang R, Burke GL, Enright PL, Newman AB, Margolis HG, Cushman M, Tracy RP, Wang Y, Kronmal RA, Barr RG. Inflammatory markers and longitudinal lung function decline in the elderly. Am J Epidemiol. 2008 Sep 15;168(6):602-10. doi: 10.1093/aje/kwn174. Epub 2008 Aug 6.</citation>
    <PMID>18687665</PMID>
  </results_reference>
  <results_reference>
    <citation>Mesia-Vela S, Yeh CC, Austin JH, Dounel M, Powell CA, Reeves A, Santella RM, Stevenson L, Yankelevitz D, Barr RG. Plasma carbonyls do not correlate with lung function or computed tomography measures of lung density in older smokers. Biomarkers. 2008 Jun;13(4):422-34. doi: 10.1080/13547500802002859 .</citation>
    <PMID>18484356</PMID>
  </results_reference>
  <results_reference>
    <citation>Jiang R, Camargo CA Jr, Varraso R, Paik DC, Willett WC, Barr RG. Consumption of cured meats and prospective risk of chronic obstructive pulmonary disease in women. Am J Clin Nutr. 2008 Apr;87(4):1002-8.</citation>
    <PMID>18400725</PMID>
  </results_reference>
  <results_reference>
    <citation>Barr RG, Stemple KJ, Mesia-Vela S, Basner RC, Derk SJ, Henneberger PK, Milton DK, Taveras B. Reproducibility and validity of a handheld spirometer. Respir Care. 2008 Apr;53(4):433-41.</citation>
    <PMID>18364054</PMID>
  </results_reference>
  <results_reference>
    <citation>Arehart E, Stitham J, Asselbergs FW, Douville K, MacKenzie T, Fetalvero KM, Gleim S, Kasza Z, Rao Y, Martel L, Segel S, Robb J, Kaplan A, Simons M, Powell RJ, Moore JH, Rimm EB, Martin KA, Hwa J. Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition. Circ Res. 2008 Apr 25;102(8):986-93. doi: 10.1161/CIRCRESAHA.107.165936. Epub 2008 Mar 6.</citation>
    <PMID>18323528</PMID>
  </results_reference>
  <results_reference>
    <citation>Lederer DJ, Benn EK, Barr RG, Wilt JS, Reilly G, Sonett JR, Arcasoy SM, Kawut SM. Racial differences in waiting list outcomes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008 Feb 15;177(4):450-4. Epub 2007 Nov 15.</citation>
    <PMID>18006881</PMID>
  </results_reference>
  <results_reference>
    <citation>Barr RG, Mesia-Vela S, Austin JH, Basner RC, Keller BM, Reeves AP, Shimbo D, Stevenson L. Impaired flow-mediated dilation is associated with low pulmonary function and emphysema in ex-smokers: the Emphysema and Cancer Action Project (EMCAP) Study. Am J Respir Crit Care Med. 2007 Dec 15;176(12):1200-7. Epub 2007 Aug 29.</citation>
    <PMID>17761614</PMID>
  </results_reference>
  <results_reference>
    <citation>Varraso R, Fung TT, Barr RG, Hu FB, Willett W, Camargo CA Jr. Prospective study of dietary patterns and chronic obstructive pulmonary disease among US women. Am J Clin Nutr. 2007 Aug;86(2):488-95.</citation>
    <PMID>17684223</PMID>
  </results_reference>
  <results_reference>
    <citation>Jones DP, Camargo CA Jr, Speizer FE, Barr RG. Prospective study of short stature and newly diagnosed asthma in women. J Asthma. 2007 May;44(4):291-5.</citation>
    <PMID>17530528</PMID>
  </results_reference>
  <results_reference>
    <citation>Jiang R, Paik DC, Hankinson JL, Barr RG. Cured meat consumption, lung function, and chronic obstructive pulmonary disease among United States adults. Am J Respir Crit Care Med. 2007 Apr 15;175(8):798-804. Epub 2007 Jan 25.</citation>
    <PMID>17255565</PMID>
  </results_reference>
  <results_reference>
    <citation>Barr RG, Bourbeau J, Camargo CA, Ram FS. Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis. Thorax. 2006 Oct;61(10):854-62. Epub 2006 Jul 14. Review. Erratum in: Thorax. 2007 Feb;62(2):191.</citation>
    <PMID>16844726</PMID>
  </results_reference>
  <results_reference>
    <citation>Jiang R, Jacobs DR Jr, Mayer-Davis E, Szklo M, Herrington D, Jenny NS, Kronmal R, Barr RG. Nut and seed consumption and inflammatory markers in the multi-ethnic study of atherosclerosis. Am J Epidemiol. 2006 Feb 1;163(3):222-31. Epub 2005 Dec 15.</citation>
    <PMID>16357111</PMID>
  </results_reference>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2009</study_first_submitted>
  <study_first_submitted_qc>February 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2009</study_first_posted>
  <last_update_submitted>January 12, 2012</last_update_submitted>
  <last_update_submitted_qc>January 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD MESA LUNG BIOMARKERS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Emphysema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

